Adversarial verification for the CKD, dialysis, and transplant frontier.
Renal disease is a $100B+ U.S. CKD/ESRD spend — one of the highest per-capita cost categories in Medicare. The dialysis-to-home transition under the CMS ETC model and value-based kidney care arrangements is reshaping roughly $30B in annual run-rate, repricing the dominant providers right now. The diabetic kidney disease intersection puts 40% of CKD patients inside an SGLT2- and Kerendia-driven repricing cycle that crosses both indications. Vision 2030 nephrology capacity is opening sovereign procurement windows from Riyadh through the wider GCC. AimwellBio runs adversarial verification across every renal signal so investors, strategy teams, and ministries operate on cited intelligence — not generative assumptions.
Adversarial verification is the cost of being early.
Intelligence Classification
The Johari Window maps renal/nephrology intelligence: what every nephrologist knows, what commercial teams miss, what companies don't disclose, and what no database has indexed.
The CMS ETC model and value-based kidney care arrangements are reshaping roughly $30B in annual dialysis run-rate. DaVita and Fresenius are repricing as home modalities, peritoneal dialysis, and integrated kidney-care contracts shift the reimbursement floor. Models built on prior in-center assumptions are silently breaking. AimwellBio tracks every CMS rule revision, MAC bulletin, and provider disclosure against the companies under your coverage.
Roughly 40% of chronic kidney disease patients are diabetic. SGLT2 inhibitors, Kerendia, and the GLP-1 cardiometabolic franchise are repricing both indications simultaneously. A renal thesis that misses the DKD intersection mis-prices the asset. AimwellBio cross-tags every signal against diabetes coverage so investment-committee and BD teams see the full exposure surface.
AimwellBio's edge is not more data. It is verified data. Every renal signal carries provenance, source method, and confidence. There is no hallucination tolerance for ministry-grade procurement or investment-committee decisions. Four independent audit agents check every brief before it is delivered.
Renal is repricing inside a regulatory, reimbursement, and sovereign-procurement window most portfolio teams will read about after it closes. The numbers below are the consequences of operating without an adversarial verification layer.
in dialysis run-rate reshaping per CMS reimbursement cycle — the ETC model and value-based kidney care contracts are repricing the dominant providers now.
of CKD patients are diabetic. A renal thesis that misses the DKD intersection mis-prices the asset and the cardiometabolic adjacency around it.
typical lag between an FDA AdComm vote and equity repricing. Investors not on the dispatch sheet are pricing yesterday’s thesis.
second chances on a Vision 2030 nephrology procurement decision. Vendors that miss the capacity buildout cycle wait until the next horizon.
Each entity is mapped into AIMN:ATLAS with scheduled-refresh SEC, ClinicalTrials.gov, PubMed, and manufacturer-disclosure coverage. Sovereign-tagged manufacturers and ministry providers across KSA, GCC, and MENA are flagged. Click any name to open its company dossier.
The sovereign roster anchors AimwellBio's renal coverage across the GCC and MENA: King Faisal Specialist Hospital Nephrology in Riyadh, Cleveland Clinic Abu Dhabi Nephrology, NMC Healthcare Renal in Abu Dhabi, SPIMACO Renal in Riyadh, and Hikma Renal in Amman. Each is monitored against SFDA filings, MOH procurement cycles, dialysis capacity expansion, and transplant program disclosures.
The same infrastructure that gives an investment committee defensible diligence gives a ministry defensible procurement. No hallucination tolerance. Every signal source-cited. Every recommendation traceable to its evidentiary chain. Sovereign deployment is not theoretical — the nephrology capacity buildout under Vision 2030 is already in motion.
Discuss sovereign deployment →Every public and pre-IPO renal name carries reimbursement, AdComm, and clinical-readout risk. Aimwell delivers cited diligence before the conviction memo, not after it.
The renal landscape moves between earnings calls. Aimwell tracks pipeline, IP, and indication-expansion signals across the full coverage universe.
Real-world evidence and KOL movement on SGLT2, Kerendia, and home-dialysis outcomes arrive faster than any single team can read. Aimwell structures the frontier into briefable units.
Source Verification
Not analyst opinion. Every data point carries its source class and freshness state.
Rendering Proof
Every claim on this page carries a label. LIVE means the source refreshes on each corpus cycle. Indexed Snapshot means fixed at the May 2026 corpus. GATED means tier access required. STATIC means analyst-sourced and manually updated.
New FDA, USRDS, NKF Guidelines, PubMed, SEC, and ClinicalTrials.gov entries ingested on each corpus refresh cycle. Source dates, confidence grades, and provenance update with each ingest.
1,706 high-confidence renal signals retained from the May 2026 corpus ingest. 40 monitored entities. Count updates at the next scheduled rebuild, not on a managed refresh cadence.
5-source adversarial PROCEED/DELAY/KILL verdict with confidence score and citation-resolution gate. Member access. ~90s generation on demand.
CMS ETC Model, value-based kidney care contract updates, and MAC LCD revisions tracked on a managed refresh cadence. Repricing signals surface before quarterly earnings calls.
Saudi MOH hemodialysis capacity expansion — 40% growth to 2028. KFSHRC, Cleveland Clinic Abu Dhabi, and regional procurement windows mapped by institution.
USRDS 2024 annual data report. Not recalculated on corpus refresh. Manually updated on major USRDS/NKF report releases.
Renal disease does not present in isolation. Roughly 40% of chronic kidney disease patients are diabetic. Cardiorenal syndrome links CKD with cardiovascular risk. ccRCC is the oncologic face of the renal equation. AimwellBio maintains a dedicated 1,706-signal renal corpus and applies cross-indication tags at filter time — so researchers drill from Renal → DKD → SGLT2 in one click without losing the broader renal context.
Designed For
SGLT2 and finerenone guideline adoption is not uniform across nephrology practices. AIMN tracks prescriber behavior lag vs. KDIGO guidelines — where the gap is, and which accounts are moving first.
Saudi MOH is expanding hemodialysis capacity by 40% to 2028. Procurement windows, tender calendars, and SFDA device registration timelines are not publicly synchronized — AIMN maps them by institution.
DaVita and Fresenius dialysis bundled payment capture rates and HIF-PHI CV safety monitoring are not in 10-K segment filings. AIMN cross-references regulatory filings, post-market registries, and payer data.
1,706 renal signals include CT.gov trial updates, KDIGO guideline revisions, ADA/KDIGO joint statement tracking, and post-market safety registry events — updated before MSL call cycle planning.
Access Tiers
Renal · Intelligence Window
CKD treatment protocols are being rewritten on a managed refresh cadence. SGLT2 adoption lags in nephrology practices while payers update formularies. Saudi MOH dialysis buildout procurement windows open before calendar year. AIMN tracks all three — source-cited, adversarially validated, delivered inside an active procurement window as of May 2026.
Running sovereign-scale renal intelligence operations? Sovereign tier starts at $50k/yr →